Physiology and pathophysiology of human gut: intestine-on-chip

Patent metadata

Field	Value
Publication number	US-12018284-B2
Application number	US-202217984023-A
Country	US
Kind code	B2
Filing date	Nov 9, 2022
Priority date	Sep 21, 2017
Publication date	Jun 25, 2024
Grant date	Jun 25, 2024

Abstract

An in vitro microfluidic intestine on-chip is described herein that mimics the structure and at least one function of specific areas of the gastrointestinal system in vivo. In particular, a multicellular, layered, microfluidic intestinal cell culture, which is some embodiments is derived from patient's enteroids-derived cells, is described comprising L cells, allowing for interactions between L cells and gastrointestinal epithelial cells, endothelial cells and immune cells. This in vitro microfluidic system can be used for modeling inflammatory gastrointestinal autoimmune tissue, e.g., diabetes, obesity, intestinal insufficiency and other inflammatory gastrointestinal disorders. These multicellular-layered microfluidic intestine on-chips further allow for comparisons between types of gastrointestinal tissues, e.g., small intestinal duodenum, small intestinal jejunum, small intestinal ileum, large intestinal colon, etc., and between disease states of gastrointestinal tissue, i.e. healthy, pre-disease and diseased areas. Additionally, these microfluidic gut-on-chips allow identification of cells and cellular derived factors driving disease states and drug testing for reducing inflammation.

First claim

What is claimed is:

1. A method of culturing intestinal cells in vitro, comprising:
a. providing i) an intestinal enteroid or colonoid comprising human primary intestinal epithelial cells, ii) a plurality of endothelial cells and iii) a microfluidic culture device comprising a cell growth region comprising a membrane having a first surface and a second surface, wherein said surfaces are on opposing sides of said membrane;
b. disrupting said intestinal enteroid or colonoid comprising human primary intestinal epithelial cells into enteroid or colonoid fragments;
c. seeding said enteroid or colonoid fragments on said first surface of said cell growth region so as to create seeded primary intestinal epithelial cells;
d. seeding endothelial cells on a second surface so as to create seeded endothelial cells, wherein said endothelial cells are seeded 1-6 days after seeding said primary intestinal epithelial cells;
e. expanding said seeded primary intestinal epithelial cells so as to create a monolayer of epithelial cells; and
f. differentiating said monolayer of epithelial cells so as to create two or more different differentiated intestinal cell types, wherein one of said two or more different differentiated intestinal cell types comprises L-cells.

2. The method of claim 1 , wherein 2 days after seeding said endothelial cells, said membrane is subject to cyclic stretching.

3. The method of claim 1 , one day after step c), starting flow.

4. The method of claim 1 , wherein said endothelial cells are selected from the group consisting of adult derived human colonic microvascular endothelial cells (cHIMECs) and pediatric sources of Human Intestinal Microvascular Endothelial Cells (HIMECs).

5. The method of claim 1 , wherein said human primary intestinal epithelial cells are from intestine tissue selected from the group consisting of a small intestinal duodenum, small intestinal jejunum, small intestinal ileum, and large intestinal colon.

Assignees

• Emulate Inc

Inventors

• Apostolou Athanasia
• Varone Antonio
• Kasendra Magdalena
• Luc Raymond

Classifications

• G01N33/5064

  Endothelial cells · CPC title

• G01N33/5047

  Cells of the immune system · CPC title

• C12N2501/25

  Tumour necrosing factors [TNF] · CPC title

• C12N2501/2306

  Interleukin-6 (IL-6) · CPC title

• C12N2501/2301

  Interleukin-1 (IL-1) · CPC title